Komori
Takara Bio (4974) · InitiativeFirst stated

Three-Brand Strategy: TaKaRa, Clontech and Cellartis

First written in FY2016. . Latest entry: FY2016.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Multi-brand expansion in Japan and overseasA theme 19 companies write about · 0 as a headwind · 22 as a tailwind

The whole theme swung hardest in 2020: 1 of 12 companies on the "Worse" side.

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.
Full recordFilings, disclosures and news, newest first
  1. FY2016First statedAnnual report

    「The Company, Clontech Laboratories, Inc., 宝生物工程（大連）有限公司 and Takara Bio Europe AB will collaborate to conduct R&D efficiently and expand globally under the three-brand strategy of TaKaRa®, Clontech® and Cellartis®, thereby strengthening and expanding the foundation of this core business.」

    Explicitly states the use of three brands for R&D collaboration and global expansion.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Takara Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Three-Brand Strategy: TaKaRa, Clontech and Cellartis | TAKARA BIO INC. (4974) | Komori